Pieris Pharmaceuticals

Pieris Pharmaceuticals, a prominent name in biotechnology research, is now merged with Palvella Therapeutics. Pieris Pharmaceuticals was dedicated to the advancement of innovative therapeutic solutions. The company’s commitment to pioneering research and development has significantly contributed to the biotechnology sector. The primary address for Pieris Pharmaceuticals is 225 Franklin Street, Boston, Massachusetts 02110, US, with an additional location at Zeppelinstraße 3, Hallbergmoos, Bavaria 85399, DE.

Pieris Pharmaceuticals focused on creating novel therapies, leveraging cutting-edge scientific approaches to address unmet medical needs. Their work encompassed a range of therapeutic areas, reflecting a broad vision for improving patient outcomes. The company's expertise and dedication positioned them as a key player in the evolving landscape of biotechnology.

To stay updated on the latest corporate news and developments, please follow @Palvella-Therapeutics. We invite the manager of Pieris Pharmaceuticals to create a customized and exclusive company showcase and product listing on our platform, ensuring continued visibility and engagement within the industry.